Shares of Spectral Medical Inc. (TSE:EDT – Get Free Report) reached a new 52-week low on Thursday . The stock traded as low as C$1.10 and last traded at C$1.15, with a volume of 35362 shares traded. The stock had previously closed at C$1.11.
Spectral Medical Price Performance
The company has a quick ratio of 0.45, a current ratio of 0.61 and a debt-to-equity ratio of 26.03. The company’s 50 day moving average is C$1.33 and its 200 day moving average is C$1.36. The firm has a market capitalization of C$328.78 million, a price-to-earnings ratio of -9.33 and a beta of 0.94.
About Spectral Medical
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ (‘PMX’). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date.
Featured Articles
- Five stocks we like better than Spectral Medical
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.
